Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Stephen V Liu, Martin Reck, Aaron S Mansfield, Tony Mok, Arnaud Scherpereel, Niels Reinmuth, Marina Chiara Garassino, Javier De Castro Carpeno, Raffaele Califano, Makoto Nishio, Francisco Orlandi, Jorge Alatorre-Alexander, Ticiana Leal, Ying Cheng, Jong-Seok Lee, Sivuonthanh Lam, Mark McCleland, Yu Deng, See Phan, Leora Horn, Stephen V Liu, Martin Reck, Aaron S Mansfield, Tony Mok, Arnaud Scherpereel, Niels Reinmuth, Marina Chiara Garassino, Javier De Castro Carpeno, Raffaele Califano, Makoto Nishio, Francisco Orlandi, Jorge Alatorre-Alexander, Ticiana Leal, Ying Cheng, Jong-Seok Lee, Sivuonthanh Lam, Mark McCleland, Yu Deng, See Phan, Leora Horn
Abstract
Purpose: IMpower133 (ClinicalTrials.gov identifier: NCT02763579), a randomized, double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-ligand 1 [PD-L1]) to carboplatin plus etoposide (CP/ET) for first-line (1L) treatment of extensive-stage small-cell lung cancer (ES-SCLC) resulted in significant improvement in overall survival (OS) and progression-free survival (PFS) versus placebo plus CP/ET. Updated OS, disease progression patterns, safety, and exploratory biomarkers (PD-L1, blood-based tumor mutational burden [bTMB]) are reported.
Patients and methods: Patients with untreated ES-SCLC were randomly assigned 1:1 to receive four 21-day cycles of CP (area under the curve 5 mg per mL/min intravenously [IV], day 1) plus ET (100 mg/m2 IV, days 1-3) with atezolizumab (1,200 mg IV, day 1) or placebo, and then maintenance atezolizumab or placebo until unacceptable toxicity, disease progression, or loss of clinical benefit. Tumor specimens were collected; PD-L1 testing was not required for enrollment. The two primary end points, investigator-assessed PFS and OS, were statistically significant at the interim analysis. Updated OS and PFS and exploratory biomarker analyses were conducted.
Results: Patients received atezolizumab plus CP/ET (n = 201) or placebo plus CP/ET (n = 202). At the updated analysis, median follow-up for OS was 22.9 months; 302 deaths had occurred. Median OS was 12.3 and 10.3 months with atezolizumab plus CP/ET and placebo plus CP/ET, respectively (hazard ratio, 0.76; 95% CI, 0.60 to 0.95; descriptive P = .0154). At 18 months, 34.0% and 21.0% of patients were alive in atezolizumab plus CP/ET and placebo plus CP/ET arms, respectively. Patients derived benefit from the addition of atezolizumab, regardless of PD-L1 immunohistochemistry or bTMB status.
Conclusion: Adding atezolizumab to CP/ET as 1L treatment for ES-SCLC continued to demonstrate improved OS and a tolerable safety profile at the updated analysis, confirming the regimen as a new standard of care. Exploratory analyses demonstrated treatment benefit independent of biomarker status.
Figures
References
- Bernhardt EB, Jalal SI: Small cell lung cancer. Cancer Treat Res 170:301-322, 2016
- National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer (Version 1.2019), 2019
- Armstrong SA, Liu SV: Dashing decades of defeat: Long anticipated advances in the first-line treatment of extensive-stage small cell lung cancer. Curr Oncol Reports 22:20, 2020
- Foster NR Renfro LA Schild SE, et al. : Multitrial evaluation of progression-free survival as a surrogate end point for overall survival in first-line extensive-stage small-cell lung cancer. J Thorac Oncol 10:1099-1106, 2015
- Horn L Mansfield AS Szczęsna A, et al. : First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379:2220-2229, 2018
- Antonia SJ Lopez-Martin JA Bendell J, et al. : Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial. Lancet Oncol 17:883-895, 2016
- Paz-Ares L Dvorkin M Chen Y, et al. : Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet 394:P1929-P1939, 2019
- TECENTRIQ (Atezolizumab) [Package Insert]. South San Francisco, CA, Genentech, 2019
- TECENTRIQ (Atezolizumab) [Summary of Product Characteristics]. Grenzach-Wyhlen, Germany, Roche Registration GmbH, 2019
- Ott PA Elez E Hiret S, et al. : Pembrolizumab in patients with extensive-stage small-cell lung cancer: Results from the phase Ib KEYNOTE-028 study. J Clin Oncol 35:3823-3829, 2017
- Chung HC Piha-Paul SA Lopez-Martin J, et al. : Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic small-cell lung cancer: Results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol 15:618-627, 2020
- Herbst RS Soria JC Kowanetz M, et al. : Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563, 2014
- Mansfield A Każarnowicz A Karaseva N, et al. : Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): A randomized phase I/III trial. Ann Oncol 31:310-317, 2020
- VENTANA PD-L1 (SP263) Assay (CE-IVD) [Package Insert]. Tucson, AZ, Ventana Medical Systems, 2018
- Tian Y Zhai X Han A, et al. : Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. J Hematol Oncol 12:67, 2019
- Kowanetz M Zou W Gettinger SN, et al. : Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1). Proc Natl Acad Sci USA 115:E10119-E10126, 2018
- Paz-Ares L Goldman JW Garassino MC, et al. : PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN. Annals Oncol 30(suppl 5):v851-v934, 2019
- Emens L Loi S Rugo H, et al. : IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab+ nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer, Cancer Res 79, 2019. (suppl; abstr GS1-04)
- Petrylak DP Powles T Bellmunt J, et al. : A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC), J Clin Oncol 33, 2015. (suppl; abstr 4501)
- Rudin CM Awad MM Navarro A, et al. : Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol 38:2369-2379, 2020
- Gandara DR Paul SM Kowanetz M, et al. : Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med 24:1441-1448, 2018
- VanderLaan PA: Fine‐needle aspiration and core needle biopsy: An update on 2 common minimally invasive tissue sampling modalities. Cancer Cytopathol 124:862-870, 2016
- Gadgeel SM Pennell NA Fidler MJ, et al. : Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC). J Thorac Oncol 13:1393-1399, 2018
- Hellmann MD Callahan MK Awad MM, et al. : Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell 33:853-861, 2018
Source: PubMed